JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

23.4 0.95

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.15

Max

23.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-6.7M

-54M

Pardavimai

-480K

695K

Pelno marža

-7,740.432

Darbuotojai

186

EBITDA

-6.7M

-62M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+132.51% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

141M

1.5B

Ankstesnė atidarymo kaina

22.45

Ankstesnė uždarymo kaina

23.4

Naujienos nuotaikos

By Acuity

50%

50%

145 / 375 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-25 17:53; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

2025-07-25 15:58; UTC

Uždarbis
Pagrindinės rinkos jėgos

Aon Shares Rise After 2Q Earnings Beat

2025-07-25 15:08; UTC

Pagrindinės rinkos jėgos

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

2025-07-25 21:40; UTC

Rinkos pokalbiai

Starbucks' Spending Hikes Are Misdirected -- Market Talk

2025-07-25 21:23; UTC

Rinkos pokalbiai

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

2025-07-25 20:40; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 20:10; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 19:56; UTC

Uždarbis

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

2025-07-25 19:14; UTC

Rinkos pokalbiai

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

2025-07-25 19:10; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

2025-07-25 19:01; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 18:45; UTC

Rinkos pokalbiai

Gold Ends Down Week on Lower Note -- Market Talk

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Sale Could Fetch Around $1B, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH in Talks to Sell Marc Jacobs -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

2025-07-25 17:38; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

2025-07-25 17:26; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Extends Decline -- Market Talk

2025-07-25 17:13; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 16:46; UTC

Uždarbis

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

2025-07-25 16:45; UTC

Uždarbis

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

2025-07-25 16:27; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-25 16:02; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

2025-07-25 15:34; UTC

Uždarbis

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

2025-07-25 15:06; UTC

Rinkos pokalbiai

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

2025-07-25 15:05; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

2025-07-25 14:45; UTC

Rinkos pokalbiai

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

2025-07-25 14:44; UTC

Rinkos pokalbiai

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

2025-07-25 14:36; UTC

Rinkos pokalbiai
Uždarbis

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

132.51% į viršų

12 mėnesių prognozė

Vidutinis 54.29 USD  132.51%

Aukščiausias 74 USD

Žemiausias 38 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

9

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

145 / 375 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.